Abstract:

Monitoring Anti-Angiogenesis Therapy

The present invention relates to a method for monitoring subjects being on anti-angiogenesis therapy based on determining the amount of a cardiac Troponin in a first and second sample of a subject and comparing the amount in said first sample with said second sample. Thereby, it can be assessed whether a subject is susceptible to a continuation of said therapy or not. Moreover, the present invention relates to a method for predicting the risk of a cardiovascular event as a consequence of anti-angiogenesis therapy. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
Monitoring anti-angiogenesis therapy

The present invention relates to a method for monitoring subjects being on anti-angiogenesis therapy based on determining the amount of a cardiac Troponin in a first and second sample of a subject and comparing the amount in said first sample with said second sample. Thereby, it can be assessed whether a subject is eligible to a continuation of said therapy or not. Moreover, the present invention relates to a method for predicting the risk of a cardiovascular event as a consequence of anti-angiogenesis therapy. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

An aim of modern medicine is to provide personalized or individualized treatment regimens. Those are treatment regimens which take into account a patient's individual needs or risks. Hyperproliferative disorders have in many cases a severe impact on the human or animal physiology. Many severe diseases, such as cancer, are caused by undesired, enhanced proliferation of cells. Specifically, cancer diseases comprise some of the most life threatening medical conditions, such as lung carcinomas which belong to the leading causes of human cancer death.

Various approaches for cancer therapy exist, e.g., surgery, chemotherapy, radiation therapy, and immunotherapy. A new, very promising cancer therapy is anti-angiogenesis therapy. The principle underlying anti-angiogenesis therapy is that tumors can grow only if new blood vessels are being formed within the blood vessels. By stopping the growth of blood vessels within the tumors with angiogenesis inhibitors, the means by which tumors can extend themselves and spread inside the body are significantly reduced. Administration of the angiogenesis inhibitor Bevacizumab (Avastin) was the first U.S. Food and Drug Administration (FDA)-approved biological therapy designed to inhibit the formation of new blood vessels in tumors. Bevacizumab itself is a monoclonal antibody against the vascular endothelial growth factor (VEGF). It was shown, e.g., that Bevacizumab significantly improves survival in metastatic colorectal cancer. The FDA has also approved other anti-angiogenic pharmaceuticals for cancer therapy, e.g. for multiple myeloma,
mantle cell lymphoma, gastrointestinal stromal tumors, and kidney cancer. More anti-
angiogenesis cancer therapies are awaiting approval.

The great beneficial effects of treating cancer patients with anti-angiogenic drugs, however, are being hampered by some problems. There is evidence that a therapy which inhibits new vessel formation has adverse side effects (particularly cardiovascular complications) and, therefore, may put some patients at risk. For example, it was shown that, e.g., sorafenib induces acute coronary syndromes in 2.9 % of patients treated with sorafenib (2007, Annals of Oncology, Volume 18. No. 11, 1906-1907).

Therefore, measures and means are required in order to (i) monitor the therapy of patients being on anti-angiogenesis therapy and to (ii) identify those subjects which would be at elevated risk of heart failure and/or acute cardiovascular events when receiving anti-angiogenic drugs.

However, such means and measures have not been described yet. Thus, the technical problem underlying the present invention can be seen as the provision of means and methods for complying with the aforementioned needs.

The technical problem is solved by the embodiments characterized in the claims and herein below.

Accordingly, the present invention relates to a method for monitoring anti-angiogenesis therapy in a subject, said subject being on anti-angiogenesis therapy, comprising the steps of

a) determining the amount of a cardiac Troponin in a first sample of said subject,
b) determining the amount of a cardiac Troponin in a second sample of said subject,
c) comparing the amount of the cardiac Troponin in said first sample as determined in step a) with the amount of the cardiac Troponin in said second sample as determined in step b),

wherein an increase of the amount as determined in step b) compared with the amount as determined in step a) indicates that said subject is not eligible to a continuation of the said anti-angiogenesis therapy.

The method of the present invention, preferably, is an in vitro method. Moreover, it may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate to sample pre-treatments or evaluation of the results obtained by the method.
The method of the present invention preferably is used for monitoring a subject being on anti-angiogenesis therapy. However, the method of the present invention may also be used for confirmation, and subclassification of said subject. The method may be carried out manually or assisted by automation. Preferably, step (a), (b) and/or (c) may in total or in part be assisted by automation, e.g., by a suitable robotic and sensory equipment for the determination in steps (a) and (b), or a computer-implemented comparison in step (c).

The term "monitoring" as used herein, preferably, relates to assessing the effects of anti-angiogenesis therapy on the subject with respect to his cardiac condition. The determination of the course of the amount of a cardiac Troponin for a subject, preferably, allows to assess the risk of adverse side effects caused by anti-angiogenesis therapy and, therefore, to make decisions on the further treatment of the said subject. Preferably, by carrying out the method of the present invention decisions can be made whether an anti-angiogenesis therapy shall be continued or stopped.

Thus, the method of the present invention allows assessing whether a subject who is on anti-angiogenesis therapy will be eligible and, thus susceptible to a continuation of an anti-angiogenesis therapy or not. It is to be understood that a subject who is eligible to a continuation of said anti-angiogenesis therapy, preferably, will not be at elevated risk of suffering from an adverse side effect of said therapy such as hypertension, heart failure, acute cardiovascular events (particularly myocardial infarction) and/or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina), whereas a subject who is not eligible to a continuation of said anti-angiogenesis therapy would be at elevated risk of suffering from an adverse side effect of said therapy when continuing said therapy. Accordingly, for a subject who is eligible to a continuation of an anti-angiogenesis therapy, the anti-angiogenesis therapy, preferably, may be continued without changing or adjusting the treatment regimen. Also, in this case, the anti-angiogenic effect of the therapy may be increased, particularly by increasing the dosage of an administered anti-angiogenic pharmaceutical, thereby allowing a more effective cancer therapy. If a subject is not eligible to a continuation of anti-angiogenesis therapy, the anti-angiogenesis therapy, preferably, is stopped in order to prevent a further deterioration of the cardiovascular condition of said subject. Also contemplated is reducing the anti-angiogenic potential of the anti-angiogenesis therapy. Reducing, the anti-angiogenic potential can be achieved by reducing the dosage of an administered anti-angiogenic pharmaceutical. However, a reduction of the dosage may be at the costs of the effectiveness of cancer therapy, i.e. may reduce the effectiveness of the cancer therapy. Particularly, anti-angiogenesis therapy may be continued for a subject not being eligible to a continuation of the said therapy (although this would putting the subject at risk of suffering from a cardiovascular complication as a
consequence of the continuation of the said therapy) if (i) treatment regimens other than anti-angiogenesis therapy (such as surgery, chemotherapy, radiation therapy) were not effective with respect to treating cancer in said subject and/or if (ii) no other treatment regimens are available and/or (iii) if the anti-angiogenesis therapy has significantly ameliorated the condition with respect to his cancer, and, thus was effective. Whether a treatment regimen intended to treat cancer was effective can be determined by methods well known in the art. It is, particularly, envisaged to assess the effectiveness by determining tumor size and/or by determining the level of carcinoembryonic antigen (CEA) in a sample of said subject. Preferably, a reduction, more preferably, a significant reduction, of tumor size as can be shown, preferably, by CT (computed tomography), MRT (magnetic resonance tomography), or PET (positron emission tomography), ultrasound examination, X-ray examination and/or by a reduction of the CEA level indicates that a treatment regimen was effective.

If an anti-angiogenesis therapy for a subject was effective with respect to treating cancer and if, however, said therapy puts said subject at risk of adverse side effects of the said therapy (particularly, an acute cardiovascular event), the medical practitioner will balance the advantages of the anti-angiogenesis therapy regarding the treatment of cancer against the disadvantages, i.e. the risk of adverse side effects of the said therapy, and, therefore, is capable of making decisions on the therapy, i.e. whether anti-angiogenesis therapy shall be continued or not. If, in this case, a treatment shall be continued, is treatment regimens shall be considered that allow improving the cardiac condition of said subject. Such treatment regimens are well known in the art (see e.g. EP1615036 Bl) and include administration of drugs as well as cardiac interventions, preferably, cardiac interventions that allow revascularisation of regions of the myocardium with reduced functionality.

Also contemplated by the present invention is that a subject who is not eligible to a continuation of anti-angiogenesis therapy, is eligible to a therapy with an PlGF antagonist, preferably with an antibody against PlGF (PlGF: Placental Growth Factor, see comments below). Therefore, the method of the present invention, in one embodiment, allows to differentiate whether a subject is eligible to anti-angiogenesis therapy or therapy with a PlGF antibody.

As will be understood by those skilled in the art, the assessment whether a subject is eligible to a continuation of cardiac therapy or not, is usually not intended to be correct for all (i.e. 100%) of the subjects to be monitored. The term, however, requires that a statistically significant portion of subjects can be correctly monitored (e.g. a cohort in a cohort study). Whether a portion is statistically significant can be determined without
further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc.. Details are found in Dowdy and Wearden, *Statistics for Research*, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99 %. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. More preferably, at least 60%, at least 70%, at least 80% or at least 90% of the subjects of a population can be properly monitored by the method of the present invention.

The term "subject" as used herein relates to animals, preferably mammals, and, more preferably, humans. However, it is envisaged in accordance with the aforementioned method of the present invention that the subject shall be on anti-angiogenesis therapy. It is particularly contemplated that said subject shall take anti-angiogenic drugs as described elsewhere herein, preferably, VEGF antagonists. A subject being on a therapy for anti-angiogenesis, preferably, is subject who suffers from cancer, and more preferably, from metastatic cancer. It is to be understood that said cancer may be any type of cancer such as neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, anaplastic thyroid carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, menigioma, medulloblastoma and peripheral neuroectodermal tumors, hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidia melanoma, seminoma, rhabdomyosarcoma, craniofaryngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmocytoma. Preferably, said cancer is A variety of cancer types are known in the art comprise neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tong carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, anaplastic thyroid carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion
carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmocytoma.

It is particularly contemplated that said cancer is selected from the group consisting of metastatic colon cancer (also known as colorectal cancer), non-small cell lung cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, metastatic prostate cancer, and pancreatic cancer.

It is also envisaged by the method of the present invention that the subject being on anti-angiogenesis therapy may suffer from diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis or psoriasis.

Moreover, it is envisaged by the present invention that the subject is at risk to suffer from a cardiovascular complication, or a subject who suffers from a cardiovascular complication, respectively. Said cardiovascular complication may be clinically apparent, but may be also clinically not apparent, yet. The method of the present invention is, particularly, beneficial for these subjects, since a continuation of anti-angiogenesis therapy may further deteriorate an already existing cardiovascular complication or increase the risk thereof. The method of the present invention allows to identify those subjects whose cardiovascular condition would deteriorate or would not deteriorate as a consequence of a continuation of anti-angiogenesis therapy.

A subject suffering from a "cardiovascular complication", preferably, may be a subject suffering from any cardiovascular disease, dysfunction, or event known to the person skilled in the art. Particularly, said subject may show clinical symptoms for ischemic heart disease, heart failure, coronary artery disease (particularly, stable coronary artery disease), ischemic heart disease, dilated cardiomyopathy, stable angina, congestive heart failure.

The subject suffering from a cardiovascular complication may show clinical symptoms (e.g. dyspnea, chest pain, see also NYHA classification below). Specifically, symptoms of
cardiovascular diseases have been classified into a functional classification system according to the New York Heart Association (NYHA). Patients of Class I have no obvious symptoms of cardiovascular disease. Physical activity is not limited, and ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. Patients of class II have slight limitation of physical activity. They are comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Patients of class III show a marked limitation of physical activity. They are comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Patients of class IV are unable to carry out any physical activity without discomfort. They show symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. Another characteristic of cardiovascular complication can be the "left ventricular ejection fraction" (LVEF) which is also known as "ejection fraction". People with a healthy heart usually have an unimpaired LVEF, which is generally described as above 50%. Most people with a systolic heart disease which is symptomatic, generally, have an LVEF of 40% or less.

Preferably, a subject suffering from a cardiovascular complication in accordance with the present invention can be allocated to an intermediated NYHA class, preferably, to NYHA class I, II or III and, most preferably, to NYHA class II.

It is also contemplated that the subject being on anti-angiogenesis therapy is a subject with an undetected cardiovascular complication (undetected at the time at which the method of the present invention is carried out; more precisely, at the moment at which the sample to be analyzed is obtained).

The term "anti-angiogenesis therapy" as used herein, preferably, encompasses those treatment regimens which aim to reduce or inhibit the formation of blood vessels (preferably of new blood vessels, more preferably, of blood vessels that deliver blood to the myocardium, and, and, thus supply the myocardium), and, thus, encompasses those treatment regimens which are capable of inhibiting angiogenesis, particularly of vessels that deliver blood to the myocardium. Said treatment regimens are well known in the art and, preferably, reduce/inhibit the formation of new vessels from pre-existing vessels and/or from endothelial precursor cells. Preferably, an anti-angiogenesis therapy relates to a drug-based therapy.

Preferably, said drugs only have low cardiotoxicity, more preferably, said drugs do not have any cardiotoxicity, and, thus, are not cardiotoxic. In the context of the present invention a drug, preferably, is considered as being cardiotoxic, if said drug induces
myocardial cell damage and/or necrosis when myocardial cells are contacted with said drug. A cardiotoxic drug in the context of the present invention is a drug that induces cardiac cell damage and/or apoptosis (preferably, myocardial cell damage and/or apoptosis of myocardial cells) when directly contacted with myocardial cells. How to determine whether a drug induces myocardial cell damage and/or apoptosis upon direct contact is well known in the art.

The method of the present invention is particularly advantageous for subjects which are treated with a VEGF antagonist (preferably, VEGF-A antagonists), particularly with antibodies specific for VEGF (preferably, specific for VEGF-A). Accordingly, the antiangiogenesis therapy, preferably, is by intake of VEGF antagonists, more preferably by intake of antibodies against VEGF, most preferably by intake of antibodies against VEGF-A. The term "VEGF antagonist", preferably, refers to a molecule being capable of inhibiting, reducing or interfering with VEGF activities including its binding to one or more VEGF receptors, particularly with the VEGF receptor 1 or 2 (VEGFR-I or VEGFR-2). WO/2008/063932, which hereby is incorporated by reference in its entirety with respect to the disclosure content, lists a variety of VEGF antagonists. Preferably, the term the antiangiogenesis therapy is by anti-VEGF antibodies that specifically bind VEGF and thereby negatively affect interaction with at least one VEGF receptor, particularly with the VEGF receptor 1 or 2 (VEGFR-I or VEGFR-2). VEGF antagonists, preferably, also encompass antisense molecules that target VEGF, RNA aptamers that target VEGF, and ribozymes that target VEGF or VEGF receptors (particularly VEGFR-I or 2).

Anti-VEGF antibodies include, but are not limited to, antibodies A4.6.1, bevacizumab (Avastin®), ranibizumab (Lucentis®, see WO98/45331 or Chen et al J Mol Biol 293:865-881 (1999)) G6, B20, 2C3, and others as described in, for example, US2003/0190317, U.S. Patents 6,582,959 and 6,703,020; WO98/45332; WO2005/044853; EP 0666868B1; and Popkov et al, Journal of Immunological Methods 288:149-164 (2004). Most preferably, the anti-VEGF antibody of the invention is bevacizumab.

Also contemplated by the method of the present invention as suitable for anti-angiogenesis therapy are antibodies against tumor necrosis factor alpha, low molecular weight tyrosine kinase inhibitors, matrix metalloproteinase inhibitors (Marimastat, AG3340, COL-3, Neovastat, BMS-275291), drugs that inhibit cell proliferation and cell migration of endothelial cells, drugs that negatively regulate stimulators of angiogenesis, drugs that stimulate the formation of endogenous angiogenesis inhibitors, drugs that inhibit binding of angiogenesis stimulators, drugs that induce apoptosis of endothelial cells, drugs that induce apoptosis of endothelial cell, and drugs that inhibit cell migration of endothelial
cells. Also contemplated by the method of the present invention are low molecular weight EGFR inhibitors (epidermal growth factor receptor antagonists) such as erlotinib, gefitinib, and lapatinib. Moreover, also contemplated are endostatin (O'Reilly et al. (1997) Cell 88: 277-285), angioatin (O'Reilly et al. (1994) Cell 79: 315-328).

It is known in the art, that antibodies against PIGF and antagonists of PIGF (PIGF: placental growth factor) are anti-angiogenic. However, antibodies were shown to inhibit growth of vessels in tumors but, presumably, not to have significant adverse side effects on the cardiovascular system (see Fischer et al., 2007, Cell, 131, 463-475). Therefore, anti-angiogenesis therapy in the context of the present invention, preferably, does not include administration of antagonists of PIGF, more preferably, the term does not include administration of an antibody that specifically binds PIGF.

The term "sample" refers to a sample of a body fluid, to a sample of separated cells or to a sample from a tissue or an organ. Samples of body fluids can be obtained by well known techniques and include, preferably, samples of blood, plasma, serum, or urine, more preferably, samples of blood, plasma or serum. Tissue or organ samples may be obtained from any tissue or organ by, e.g., biopsy. Separated cells may be obtained from the body fluids or the tissues or organs by separating techniques such as centrifugation or cell sorting. Preferably, cell-, tissue- or organ samples are obtained from those cells, tissues or organs which express or produce the peptides referred to herein.

Preferably, the first sample in the context of the present invention is obtained prior to the start of the anti-angiogenesis therapy. More preferably, the first sample is obtained shortly prior to said anti-angiogenesis therapy. Even more preferably, the sample is obtained within 1 hour, within 12 hours, within 24 hours, within one week, or within 2 weeks before the said therapy is started. Since the aforementioned method of the present invention comprises the assessment of changes of the amounts of biomarkers that are caused by an anti-angiogenesis treatment regimen, the first sample may also be obtained after the start of anti-angiogenesis therapy (but before the second sample is obtained).

Thus, the second sample, preferably, is obtained (i) after the first sample, and (ii) after the start of the anti-angiogenesis therapy. Regarding (i), it is particularly contemplated that the second sample is obtained after a reasonable period of time after obtaining the first sample. It is to be understood, that the amounts of biomarkers referred herein, do not instantly change (e.g. within 1 minute or 1 hour) after anti-angiogenesis therapy is started. Therefore, "reasonable" in this context refers to intervals between obtaining the first and second sample which intervals allow the biomarker(s) to adjust. Therefore (with respect to
(i)), the second sample, preferably, is obtained at least one week or more after said first sample, two weeks week or more after said first sample, four weeks or more after said first sample, two months or more after said first sample, or three months, or six months or more after the first sample (or after treatment initiation). It is particularly contemplated to obtain the second sample four weeks after said first sample (or after treatment initiation).

It is also envisaged to assess the time course of the amount of a cardiac Troponin. Accordingly, the aforementioned method may comprise the additional step of determining the amount of a cardiac Troponin in at least one further sample from said subject (thus, in a third sample, in a fourth sample, in a fifth sample etc.) and comparing the, thus, determined amount with the amount of said cardiac Troponin in said first sample and/or said second sample and/or any sample that was obtained before said at least one further sample was obtained. For preferred time intervals for obtaining the samples, please see above.

The term "cardiac Troponin" refers to all Troponin isoforms expressed in cells of the heart and, preferably, the subendocardial cells. These isoforms are well characterized in the art as described, e.g., in Anderson 1995, Circulation Research, vol. 76, no. 4: 681-686 and Ferrieres 1998, Clinical Chemistry, 44: 487-493. Preferably, cardiac Troponin refers to Troponin T and/or Troponin I. The most preferred cardiac Troponin in the context of the present invention is Troponin T.

Amino acid sequences for human Troponin T and human Troponin I are disclosed in Anderson, loc cit and Ferrieres 1998, Clinical Chemistry, 44: 487-493. The term "cardiac Troponin" encompasses also variants of the aforementioned specific Troponins, i.e., preferably, of Troponin T or Troponin I. Such variants have at least the same essential biological and immunological properties as the specific cardiac Troponins. In particular, they share the same essential biological and immunological properties if they are detectable by the same specific assays referred to in this specification, e.g., by ELISA Assays using polyclonal or monoclonal antibodies specifically recognizing the said cardiac Troponins. Moreover, it is to be understood that a variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and/or addition wherein the amino acid sequence of the variant is still, preferably, at least 50 %, 60 %, 70 %, 80 %, 85 %, 90 %, 92 %, 95 %, 97 %, 98 %, or 99 % identical with the amino sequence of the specific Troponin. The degree of identity between two amino acid sequences can be determined by algorithms well known in the art. Preferably, the degree of identity is to be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or
overhangs) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Add. APL. Math. 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad Sci. (USA) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used. Variants referred to above may be allelic variants or any other species specific homologs, paralogs, or orthologs. Moreover, the variants referred to herein include fragments of the specific polypeptides or the aforementioned types of variants as long as these fragments have the essential immunological and biological properties as referred to above. Such fragments may be, e.g., degradation products of the polypeptides. Further included are variants which differ due to posttranslational modifications such as phosphorylation or myristylation.

Determining the amount of the peptides or polypeptides referred to in this specification relates to measuring the amount or concentration, preferably semi-quantitatively or quantitatively. Measuring can be done directly or indirectly. Direct measuring relates to measuring the amount or concentration of the peptide or polypeptide based on a signal which is obtained from the peptide or polypeptide itself and the intensity of which directly correlates with the number of molecules of the peptide present in the sample. Such a signal - sometimes referred to herein as intensity signal - may be obtained, e.g., by measuring an intensity value of a specific physical or chemical property of the peptide or polypeptide. Indirect measuring includes measuring of a signal obtained from a secondary component (i.e. a component not being the peptide or polypeptide itself) or a biological read out system, e.g., measurable cellular responses, ligands, labels, or enzymatic reaction products.

In accordance with the present invention, determining the amount of a peptide or polypeptide can be achieved by all known means for determining the amount of a peptide in a sample. Said means comprise immunoassay devices and methods which may utilize
labeled molecules in various sandwich, competition, or other assay formats. Said assays will develop a signal which is indicative for the presence or absence of the peptide or polypeptide. Moreover, the signal strength can, preferably, be correlated directly or indirectly (e.g. reverse-proportional) to the amount of polypeptide present in a sample.

Further suitable methods comprise measuring a physical or chemical property specific for the peptide or polypeptide such as its precise molecular mass or NMR spectrum. Said methods comprise, preferably, biosensors, optical devices coupled to immunoassays, biochips, analytical devices such as mass-spectrometers, NMR-analyzers, or chromatography devices. Further, methods include micro-plate ELISA-based methods, fully-automated or robotic immunoassays (available for example on Elecsys™ analyzers), CBA (an enzymatic Cobalt Binding Assay, available for example on Roche-Hitachi™ analyzers), and latex agglutination assays (available for example on Roche-Hitachi™ analyzers).

Preferably, determining the amount of a peptide or polypeptide comprises the steps of (a) contacting a cell capable of eliciting a cellular response the intensity of which is indicative of the amount of the peptide or polypeptide with the said peptide or polypeptide for an adequate period of time, (b) measuring the cellular response. For measuring cellular responses, the sample or processed sample is, preferably, added to a cell culture and an internal or external cellular response is measured. The cellular response may include the measurable expression of a reporter gene or the secretion of a substance, e.g. a peptide, polypeptide, or a small molecule. The expression or substance shall generate an intensity signal which correlates to the amount of the peptide or polypeptide.

Also preferably, determining the amount of a peptide or polypeptide comprises the step of measuring a specific intensity signal obtainable from the peptide or polypeptide in the sample. As described above, such a signal may be the signal intensity observed at an m/z variable specific for the peptide or polypeptide observed in mass spectra or a NMR spectrum specific for the peptide or polypeptide.

Determining the amount of a peptide or polypeptide may, preferably, comprises the steps of (a) contacting the peptide with a specific ligand, (b) (optionally) removing non-bound ligand, (c) measuring the amount of bound ligand. The bound ligand will generate an intensity signal. Binding according to the present invention includes both covalent and non-covalent binding. A ligand according to the present invention can be any compound, e.g., a peptide, polypeptide, nucleic acid, or small molecule, binding to the peptide or polypeptide described herein. Preferred ligands include antibodies, nucleic acids, peptides or polypeptides such as receptors or binding partners for the peptide or polypeptide and
fragments thereof comprising the binding domains for the peptides, and aptamers, e.g.,
nucleic acid or peptide aptamers. Methods to prepare such ligands are well-known in the
art. For example, identification and production of suitable antibodies or aptamers is also
offered by commercial suppliers. The person skilled in the art is familiar with methods to
develop derivatives of such ligands with higher affinity or specificity. For example,
random mutations can be introduced into the nucleic acids, peptides or polypeptides. These
derivatives can then be tested for binding according to screening procedures known in the
art, e.g. phage display. Antibodies as referred to herein include both polyclonal and
monoclonal antibodies, as well as fragments thereof, such as Fv, Fab and F(ab)_2 fragments
that are capable of binding antigen or hapten. The present invention also includes single
chain antibodies and humanized hybrid antibodies wherein amino acid sequences of a non-
human donor antibody exhibiting a desired antigen-specificity are combined with
sequences of a human acceptor antibody. The donor sequences will usually include at least
the antigen-binding amino acid residues of the donor but may comprise other structurally
and/or functionally relevant amino acid residues of the donor antibody as well. Such
hybrids can be prepared by several methods well known in the art. Preferably, the ligand or
agent binds specifically to the peptide or polypeptide. Specific binding according to the
present invention means that the ligand or agent should not bind substantially to ("cross-
react" with) another peptide, polypeptide or substance present in the sample to be
analyzed. Preferably, the specifically bound peptide or polypeptide should be bound with
at least 3 times higher, more preferably at least 10 times higher and even more preferably
at least 50 times higher affinity than any other relevant peptide or polypeptide. Non-
specific binding may be tolerable, if it can still be distinguished and measured
unequivocally, e.g. according to its size on a Western Blot, or by its relatively higher
abundance in the sample. Binding of the ligand can be measured by any method known in
the art. Preferably, said method is semi-quantitative or quantitative. Suitable methods are
described in the following.
First, binding of a ligand may be measured directly, e.g. by NMR or surface plasmon
coupling.
Second, if the ligand also serves as a substrate of an enzymatic activity of the peptide or
polypeptide of interest, an enzymatic reaction product may be measured (e.g. the amount
of a protease can be measured by measuring the amount of cleaved substrate, e.g. on a
Western Blot). Alternatively, the ligand may exhibit enzymatic properties itself and the
"ligand peptide or polypeptide" complex or the ligand which was bound by the peptide or
polypeptide, respectively, may be contacted with a suitable substrate allowing detection by
the generation of an intensity signal. For measurement of enzymatic reaction products,
preferably the amount of substrate is saturating. The substrate may also be labeled with a
detectable label prior to the reaction. Preferably, the sample is contacted with the substrate
for an adequate period of time. An adequate period of time refers to the time necessary for a detectable, preferably measurable, amount of product to be produced. Instead of measuring the amount of product, the time necessary for appearance of a given (e.g. detectable) amount of product can be measured.

Third, the ligand may be coupled covalently or non-covalently to a label allowing detection and measurement of the ligand. Labelling may be done by direct or indirect methods. Direct labelling involves coupling of the label directly (covalently or non-covalently) to the ligand. Indirect labelling involves binding (covalently or non-covalently) of a secondary ligand to the first ligand. The secondary ligand should specifically bind to the first ligand.

Said secondary ligand may be coupled with a suitable label and/or be the target (receptor) of tertiary ligand binding to the secondary ligand. The use of secondary, tertiary or even higher order ligands is often used to increase the signal. Suitable secondary and higher order ligands may include antibodies, secondary antibodies, and the well-known streptavidin-biotin system (Vector Laboratories, Inc.). The ligand or substrate may also be "tagged" with one or more tags as known in the art. Such tags may then be targets for higher order ligands. Suitable tags include biotin, digoxygenin, His-Tag, Glutathion-S-Transferase, FLAG, GFP, myc-tag, influenza A virus haemagglutinin (HA), maltose binding protein, and the like. In the case of a peptide or polypeptide, the tag is preferably at the N-terminus and/or C-terminus. Suitable labels are any labels detectable by an appropriate detection method. Typical labels include gold particles, latex beads, acridan ester, luminol, ruthenium, enzymatically active labels, radioactive labels, magnetic labels ("e.g. magnetic beads", including paramagnetic and superparamagnetic labels), and fluorescent labels. Enzymatically active labels include e.g. horseradish peroxidase, alkaline phosphatase, beta-Galactosidase, Luciferase, and derivatives thereof. Suitable substrates for detection include di-amino-benzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT-BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate, available as ready-made stock solution from Roche Diagnostics), CDP-Star™ (Amersham Biosciences), ECF™ (Amersham Biosciences). A suitable enzyme-substrate combination may result in a colored reaction product, fluorescence or chemoluminescence, which can be measured according to methods known in the art (e.g. using a light-sensitive film or a suitable camera system). As for measuring the enzymatic reaction, the criteria given above apply analogously. Typical fluorescent labels include fluorescent proteins (such as GFP and its derivatives), Cy3, Cy5, Texas Red, Fluorescein, and the Alexa dyes (e.g. Alexa 568). Further fluorescent labels are available e.g. from Molecular Probes (Oregon). Also the use of quantum dots as fluorescent labels is contemplated. Typical radioactive labels include ^{35}S, ^{125}I, ^{32}P, ^{33}P and the like. A radioactive label can be detected by any method known and appropriate, e.g. a light-sensitive film or a phosphor imager. Suitable measurement methods according the present invention also include precipitation
(particularly immunoprecipitation), electrochemiluminescence (electro-generated chemiluminescence), RIA (radioimmunoassay), ELISA (enzyme-linked immunosorbent assay), sandwich enzyme immune tests, electrochemiluminescence sandwich immunoassays (ECLIA), dissociation-enhanced lanthanide fluoro immuno assay (DELFIA), scintillation proximity assay (SPA), turbidimetry, nephelometry, latex-enhanced turbidimetry or nephelometry, or solid phase immune tests. Further methods known in the art (such as gel electrophoresis, 2D gel electrophoresis, SDS polyacrylamid gel electrophoresis (SDS-PAGE), Western Blotting, and mass spectrometry), can be used alone or in combination with labelling or other detection methods as described above.

The amount of a peptide or polypeptide may be, also preferably, determined as follows: (a) contacting a solid support comprising a ligand for the peptide or polypeptide as specified above with a sample comprising the peptide or polypeptide and (b) measuring the amount peptide or polypeptide which is bound to the support. The ligand, preferably chosen from the group consisting of nucleic acids, peptides, polypeptides, antibodies and aptamers, is preferably present on a solid support in immobilized form. Materials for manufacturing solid supports are well known in the art and include, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracycles, wells and walls of reaction trays, plastic tubes etc. The ligand or agent may be bound to many different carriers. Examples of well-known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the invention. Suitable methods for fixing/immobilizing said ligand are well known and include, but are not limited to ionic, hydrophobic, covalent interactions and the like. It is also contemplated to use "suspension arrays" as arrays according to the present invention (Nolan 2002, Trends Biotechnol. 20(1):9-12). In such suspension arrays, the carrier, e.g. a microbead or microsphere, is present in suspension. The array consists of different microbeads or microspheres, possibly labeled, carrying different ligands. Methods of producing such arrays, for example based on solid-phase chemistry and photo-labile protective groups, are generally known (US 5,744,305).

The term "amount" as used herein encompasses the absolute amount of a polypeptide or peptide, the relative amount or concentration of the said polypeptide or peptide as well as any value or parameter which correlates thereto or can be derived therefrom. Such values or parameters comprise intensity signal values from all specific physical or chemical properties obtained from the said peptides by direct measurements, e.g., intensity values in
mass spectra or NMR spectra. Moreover, encompassed are all values or parameters which are obtained by indirect measurements specified elsewhere in this description, e.g., response levels determined from biological read out systems in response to the peptides or intensity signals obtained from specifically bound ligands. It is to be understood that values correlating to the aforementioned amounts or parameters can also be obtained by all standard mathematical operations.

The term "comparing" as used herein encompasses comparing the amount of the peptide or polypeptide comprised by the a sample of a subject, preferably by the first sample, to be analyzed with an amount in another sample of said subject, preferably, in the second sample. It is to be understood that comparing as used herein refers to a comparison of corresponding parameters or values, e.g., an absolute amount is compared to an absolute reference while a concentration is compared to a concentration or an intensity signal obtained from a sample of a subject is compared to the same type of intensity signal of another sample of said subject. The comparison referred to in step (c) of the method of the present invention may be carried out manually or computer assisted. For a computer assisted comparison, the value of the determined amount may be compared to values corresponding to suitable references which are stored in a database by a computer program. The computer program may further evaluate the result of the comparison, i.e. automatically provide the desired assessment in a suitable output format. Based on the comparison of the amount in a sample of a subject as determined in the context of the present (preferably the first sample) with another sample of said subject (preferably, the second sample or the at least one further sample), it is possible to assess whether a subject is eligible to a continuation of the anti-angiogenesis therapy or not.

As mentioned above, the assessment whether a subject is eligible to a continuation of anti-angiogenesis therapy is based on the comparison of the amount of a marker of the present invention in one sample of a subject (preferably, in the first sample) with amount of the respective marker in another sample of that subject (preferably, in said second sample) that is obtained after a reasonable time interval after said one, preferably, said first sample.

Preferably, an increase and, more preferably, a significant increase, and, most preferably, a statistically significant increase of the amount of a cardiac Troponin in the second sample compared with the first sample is indicative for a subject not being eligible to a continuation of anti-angiogenesis therapy.

Particularly, a significant increase is an increase of a size which is considered to be significant for diagnosis, particularly said increase is considered statistically significant.
The terms "significant" and "statistically significant" are known by the person skilled in the art. Thus, whether an increase is significant or statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools.

Preferred significant increases of the amount of a cardiac Troponin, preferably of the amount of Troponin T in a blood serum sample, which have been found in the course of the invention to be indicative for a subject who is not eligible to a continuation of anti-angiogenesis therapy are given below.

According to the invention, an increase of the amount of a cardiac Troponin in the second sample compared to the amount in the first sample (or in a sample compared with the amount in a sample that was obtained earlier), preferably, of at least 2 pg/ml, more preferably of at least 3 pg/ml and even, more preferably, of at least 4 pg/ml, of at least 5 pg/ml, or of at least 7 pg/ml, of at least 10 pg/ml and most preferably of at least 20 pg/ml is considered to be significant and, thus, to be indicative for a subject who is not eligible to a continuation of anti-angiogenesis therapy. Preferably, the aforementioned increases are drawn to an interval of 2 or 3 months between obtaining the first and second sample (thus for the case that the second sample was obtained 2 or 3 month after the first sample or after 2 or 3 month of treatment).

If the percentage increase is determined, an increase of the amount of a cardiac Troponin in the second sample compared to the amount in the first sample, preferably, of at least 15 %, of at least 20 %, more preferably of at least 40 %, and even more preferably, of at least 60 %, of at least 80 %, of at least 100 % and most preferably of at least 200 % is considered to be significant and, thus, to be indicative for a subject who is not eligible to a continuation of anti-angiogenesis therapy. Preferably, the aforementioned increases are drawn to an interval of 2 or 3 month between obtaining the first and second sample.

It is to be understood that an decrease of the amount of a cardiac Troponin or unchanged amounts of a cardiac Troponin in a later obtained sample (preferably the second sample) compared with an earlier obtained sample (preferably, the first sample), or an insignificant increase is preferably indicative for a subject who is eligible to a continuation of anti-angiogenesis therapy.

Once it has been assessed whether a subject is not eligible to anti-angiogenesis therapy, a suitable decision on treatment as described elsewhere in this specification can be made.
Tumor patients treated with anti-angiogenic pharmaceuticals, particularly with VEGF antibodies and antagonist are at increased risk of hypertension, heart failure, acute cardiovascular event (particularly myocardial infarction) and/or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina) as a consequence of the said therapy (see above). Advantageously, the studies carried out in the context of the present invention strongly suggest that determining the amount of a cardiac Troponin in a first and a second sample of a subject and comparing the amount of said cardiac Troponin in said first sample with the amount of said cardiac Troponin in said second sample allows reliably assessing whether a subject who is on anti-angiogenesis therapy is eligible to a continuation of said therapy or not. The findings of the present invention are particularly advantageous for subject receiving VEGF-inhibitors (particularly, antibodies against VEGF) since those subjects are, as a result of the intake of those inhibitors, of increased risk of suffering from cardiovascular complications, particularly of suffering from acute coronary syndromes. Thanks to the present invention, an easy, rapid and reliable risk stratification can be carried out. Preferably, if the amount of a cardiac Troponin of a subject being on anti-angiogenesis therapy increases during the course of the said therapy (more preferably increase significantly), said subject is not considered to be eligible to a continuation of the said therapy. Preferably, if the amount of a cardiac Troponin for a subject being on anti-angiogenesis therapy does not increase or does only increase insignificantly, then said subject is eligible to a continuation of the said therapy.

Moreover, the aforementioned method of the present invention, preferably, further comprises the step of determining the amount of natriuretic peptide in said first sample and in said second sample of said subject (and optionally in at least one further sample) and comparing the amount of said natriuretic peptide as determined for said first sample with the amount of said natriuretic peptide in said second sample. Preferably, an increase of the amount of a natriuretic peptide in the time course of an anti-angiogenesis therapy (particularly, an increase of the amount in the second sample compared with the amount in the first sample), more preferably a significant increase, and most preferably, a statistically significant increase is indicative for a subject not being eligible to a continuation of said therapy (if also the amount of a cardiac Troponin is also increased as described herein above). Accordingly, a decrease of the amount of said natriuretic peptide or an insignificant increase of said amount in a second sample compared with a first sample (or unchanged amounts), preferably, indicate that a subject is susceptible to a continuation of said therapy (if also the amount of a cardiac Troponin indicated the same)

The term "natriuretic peptide" comprises Atrial Natriuretic Peptide (ANP)-type and Brain Natriuretic Peptide (BNP)-type peptides and variants thereof having the same predictive
potential. Natriuretic peptides according to the present invention comprise ANP-type and BNP-type peptides and variants thereof (see e.g. Bonow, 1996, Circulation 93: 1946-1950). ANP-type peptides comprise pre-proANP, proANP, NT-proANP, and ANP. BNP-type peptides comprise pre-proBNP, proBNP, NT-proBNP, and BNP. The pre-pro peptide (134 amino acids in the case of pre-proBNP) comprises a short signal peptide, which is enzymatically cleaved off to release the pro peptide (108 amino acids in the case of proBNP). The pro peptide is further cleaved into an N-terminal pro peptide (NT-pro peptide, 76 amino acids in case of NT-proBNP) and the active hormone (32 amino acids in the case of BNP, 28 amino acids in the case of ANP). Preferred natriuretic peptides according to the present invention are NT-proANP, ANP, NT-proBNP, BNP, and variants thereof. ANP and BNP are the active hormones and have a shorter half-life than their respective inactive counterparts, NT-proANP and NT-proBNP. BNP is metabolised in the blood, whereas NT-proBNP circulates in the blood as an intact molecule and as such is eliminated renally. The in-vivo half-life of NTproBNP is 120 min longer than that of BNP, which is 20 min (Smith 2000, J Endocrinol. 167: 239-46.). Preanalytics are more robust with NT-proBNP allowing easy transportation of the sample to a central laboratory (Mueller 2004, Clin Chem Lab Med 42: 942-4.). Blood samples can be stored at room temperature for several days or may be mailed or shipped without recovery loss. In contrast, storage of BNP for 48 hours at room temperature or at 4° Celsius leads to a concentration loss of at least 20 % (Mueller loc.cit; Wu 2004, Clin Chem 50: 867-73.). Therefore, depending on the time-course or properties of interest, either measurement of the active or the inactive forms of the natriuretic peptide can be advantageous. More preferred natriuretic peptides according to the present invention are BNP and NT-proBNP or variants thereof. The most preferred natriuretic peptides according to the present invention are NT-proBNP or variants thereof. As briefly discussed above, the human NT-proBNP, as referred to in accordance with the present invention, is a polypeptide comprising, preferably, 76 amino acids in length corresponding to the N-terminal portion of the human NT-proBNP molecule. The structure of the human BNP and NT-proBNP has been described already in detail in the prior art, e.g., WO 02/089657, WO 02/083913 or Bonow loc. cit. Preferably, human NT-proBNP as used herein is human NT-proBNP as disclosed in EP 0 648 228 B1. These prior art documents are herewith incorporated by reference with respect to the specific sequences of NT-proBNP and variants thereof disclosed therein. The NT-proBNP referred to in accordance with the present invention further encompasses allelic and other variants of said specific sequence for human NT-proBNP discussed above. Specifically, envisaged are variant polypeptides which are on the amino acid level at least 60 % identical, more preferably at least 70 %, at least 80 %, at least 90 %, at least 95 %, at least 98 % or at least 99 % identical, to human NT-proBNP. How to determine the degree of identity is specified elsewhere herein. Substantially similar
and also envisaged are proteolytic degradation products which are still recognized by the
diagnostic means or by ligands directed against the respective full-length peptide. Also
encompassed are variant polypeptides having amino acid deletions, substitutions, and/or
additions compared to the amino acid sequence of human NT-proBNP as long as the said
polypeptides have NT-proBNP properties. NT-proBNP properties as referred to herein are
immunological and/or biological properties. Preferably, the NT-proBNP variants have
immunological properties (i.e. epitope composition) comparable to those of NT-proBNP.
Thus, the variants shall be recognizable by the aforementioned means or ligands used for
determination of the amount of the natriuretic peptides. Biological and/or immunological
NT-proBNP properties can be detected by the assay described in Karl et al. (Karl 1999,
Scand J Clin Invest 230:177-181), Yeo et al. (Yeo 2003, Clinica Chimica Acta 338:107-
115). Variants also include posttranslationally modified peptides such as glycosylated
peptides. Further, a variant in accordance with the present invention is also a peptide or
polypeptide which has been modified after collection of the sample, for example by
covalent or non-covalent attachment of a label, particularly a radioactive or fluorescent
label, to the peptide.

Preferably, an increase and, more preferably, a significant increase, and, most preferably, a
statistically significant increase of a natriuretic peptide in the second sample of the subject
compared with the first sample of the subject is indicative for a subject not being eligible to
a continuation of said anti-angiogenesis therapy (if also the amount of a cardiac Troponin
is increased in said second sample compared with said first sample as described herein).

Preferred significant increases of the amount of a natriuretic peptide, preferably of the
amount of NT-proBNP in a blood serum sample, which have been found in the course of
the invention to be indicative for a subject who is not eligible to a continuation of anti-
angiogenesis therapy are given below.

According to the invention, an increase of the amount of a natriuretic peptide in the second
sample compared with the amount in the first sample, preferably, of at least 40 pg/ml, more
preferably of at least 60 pg/ml and even, more preferably, of at least 80 pg/ml, of at least
100 pg/ml, or of at least 150 pg/ml, of at least 200 pg/ml and most preferably of at least
300 pg/ml is considered to be significant and, thus, to be indicative for a subject who is not
eligible to a continuation of anti-angiogenesis therapy. Preferably, the aforementioned
increases are drawn to an interval of 2 or 3 month between obtaining the first and second
sample.
If the percentage increase is determined, an increase of the amount of a natriuretic peptide in the second sample compared to the amount in the first sample, preferably, of at least 15%, of at least 20%, more preferably of at least 40%, and even more preferably, of at least 60%, of at least 80%, of at least 100% and most preferably of at least 200% is considered to be significant and, thus, to be indicative for a subject who is not eligible to a continuation of anti-angiogenesis therapy. Preferably, the aforementioned increases are drawn to an interval of 2 or 3 months between obtaining the first and second sample.

It is to be understood that in case of decreased or unchanged amounts of the amount of a natriuretic peptide in a later obtained sample (preferably the second sample) compared with an earlier obtained sample (preferably, the first sample) or in case of an increase that is not significant, the subject, preferably, is eligible to a continuation of anti-angiogenesis therapy (see also above).

It is to be understood that the definitions and explanations of the terms made above and below apply mutatis mutandis for all embodiments/methods described in this specification and the accompanying claims (except if the contrary is indicated).

It is also envisaged in the context of the present invention that a subject is also not eligible to a continuation of an anti-angiogenesis therapy, if the amount of a cardiac Troponin in sample obtained during the said-anti-angiogenesis therapy is larger than a reference amount.

Accordingly, the present invention relates to a method for identifying a subject who is eligible to a continuation of an anti-angiogenesis therapy, said subject being on anti-angiogenesis therapy, comprising the steps of

a) determining the amount of a cardiac Troponin in a sample of said subject, 
b) comparing the amount of a cardiac Troponin as determined in step a) with a suitable reference amount for a cardiac Troponin, and 
c) identifying a subject being eligible to a continuation of anti-angiogenesis therapy.

The term "identifying" as used herein means assessing whether a subject who is on anti-angiogenesis therapy will be eligible (and, thus susceptible) to a continuation of an anti-angiogenesis therapy or not. It is to be understood that a subject who is eligible to a continuation of said anti-angiogenesis therapy, preferably, will not be at elevated risk of
suffering from adverse side effects of said therapy such hypertension, heart failure, acute cardiovascular event (particularly myocardial infarction) and/or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina) as a consequence of the said therapy, whereas a subject who is not eligible to a continuation of said anti-angiogenesis therapy would be of elevated risk of suffering from adverse side effects of the said therapy. As will be understood by those skilled in the art, such an assessment is usually not intended to be correct for all (i.e. 100%) of the subjects to be identified. The term, however, requires that a statistically significant portion of subjects can be identified (e.g. a cohort in a cohort study). Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc. Details are found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. More preferably, at least 60%, at least 70%, at least 80% or at least 90% of the subjects of a population can be properly identified by the method of the present invention.

The sample in the context of the aforementioned method, preferably, is obtained after starting the anti-angiogenesis therapy. More preferably, said sample is obtained after at least four weeks, at least two month, at least three months, at least four months, or at least six months after starting anti-angiogenesis therapy. It is particularly contemplated to obtain said sample three months after the start of anti-angiogenesis therapy.

Preferably, the term "reference amounts" as used herein refers to amounts of the polypeptides which allows for identifying a subject being eligible or not being eligible to a continuation of anti-angiogenesis therapy. Accordingly, the reference may either be derived from (i) a subject known to be eligible to a continuation of said anti-angiogenesis therapy (particularly a subject who did not suffer from adverse side effects of the therapy such hypertension, heart failure, acute cardiovascular event (particularly myocardial infarction) and/or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina) as a consequence of the said therapy) or (ii) a subject which is known not to be eligible to a continuation of anti-angiogenesis therapy (particularly a subject who suffered from an adverse side effect of the said therapy). Preferably, said subject received the same therapy as the subject whose sample is analyzed in the context of the present invention. Moreover, the reference amounts, preferably, define thresholds. Suitable reference amounts or threshold amounts may be determined by the method of the present invention from a reference sample to be analyzed together, i.e. simultaneously or
subsequently, with the test sample. A preferred reference amount serving as a threshold may be derived from the upper limit of normal (ULN), i.e. the upper limit of the physiological amount to be found in a population of subjects (e.g. patients enrolled for a clinical trial). The ULN for a given population of subjects can be determined by various well known techniques.

More preferably, a reference will be obtained by determining the values for the at least one characteristic feature for a group of reference subjects, i.e. a group of subjects known a subject known to be eligible to a continuation of anti-angiogenesis therapy, a group of subjects known not to be eligible to a continuation of said anti-angiogenesis therapy, a population comprising the subject to be investigated and calculating the reference by appropriate statistic measures including those referred to elsewhere herein, such as median, average, quantiles, PLS-DA, logistic regression methods, random forest classification or others that give a threshold value. The threshold value should take the desired clinical settings of sensitivity and specificity of the diagnostic and prognostic test into consideration.

Thus, the reference amount defining a threshold amount for a cardiac Troponin, and preferably, for Troponin T as referred to in accordance with the present invention is, preferably, 7 pg/ml, or 10 pg/ml, and, more preferably, 25 pg/ml and, even more preferably, 15 pg/ml.

Preferably, an amount of a cardiac Troponin lower than the reference amount for said cardiac Troponin indicates that said subject is eligible to a continuation of anti-angiogenesis therapy.

Preferably, an amount of a cardiac Troponin larger than the reference amount for said cardiac Troponin indicates that said subject is not eligible to a continuation of anti-angiogenesis therapy. For said subject a therapy other than an anti-angiogenesis therapy, preferably, shall be considered. However, said subject, preferably, is eligible to a therapy with PIGF antagonists, particularly, an anti-PIGF antibody.

Experiments carried out in the context of the present invention strongly suggest that subjects with increased levels of a cardiac Troponin shall not continue a anti-angiogenesis therapy since these patients are at elevated risk of suffering from adverse side effects of the said therapy, particularly acute cardiovascular events in the future. Specifically, the amount
of Troponin T was determined in serum samples of a patient cohort comprising patients with various tumors was determined. The experiments showed that the prevalence of cardiovascular complications in tumor patients is much higher than suspected and that there is a clear need to identify those subjects which are less likely to benefit from anti-angiogenesis therapy particularly, those subjects with previously undetected cardiovascular complications. In case the patient turns out to eligible for a continuation of anti-angiogenesis therapy a cost intensive therapy that would put said subject at risk can be avoided.

Moreover, the method of the present invention is advantageous since it can be implemented in portable systems, such as test stripes.

Taken together, patients with increased Troponin T amounts are at increased risk of suffering from various disorders as referred to herein when taking anti-angiogenic medication (as a result to said therapy). Patients with amounts that are not increased are not at elevated risk of suffering from the said disorders when taking anti-angiogenic medication.

Moreover, in addition to Troponin T, also the amount of NT-proBNP was determined in samples of the patients referred to above. It was shown, that the determination of NT-proBNP adds further diagnostic and prognostic value. The results indicate that subjects who take anti-angiogenic drugs and which have increased levels of both NT-proBNP and Troponin T are at increased risk of suffering from an adverse side effect such as hypertension, heart failure, an acute cardiovascular event (particularly myocardial infarction) and/or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina) as a consequence of the said therapy, particularly of acute cardiovascular events. Thus, when determining both a natriuretic peptide and cardiac Troponin a statistically more significant proportion of subjects can be correctly identified compared to determining only cardiac Troponin alone. However, the determination of a cardiac Troponin alone already allows reliably identifying subjects with a high significance.

Accordingly, the aforementioned method further may comprise determining the amount of a natriuretic peptide in a sample of the subject and comparing the, thus, determined amount with a reference amount for a natriuretic peptide.

Preferably, a reference amount defining a threshold amount for natriuretic peptide, and preferably, for NT-proBNP, as referred to in accordance with the present invention is, 250
pg/ml, more preferably 300 pg/ml, even more preferably 400 pg/ml and, most preferably, 500 or 1000 pg/ml.

Preferably, an amount of a cardiac Troponin lower than the reference amount for said cardiac Troponin, and an amount a natriuretic peptide lower than the reference amount for said natriuretic peptide indicates that said subject is eligible to a continuation of said anti-angiogenesis therapy.

Preferably, an amount of a cardiac Troponin larger than the reference amount for said cardiac Troponin, and an amount a natriuretic peptide larger than the reference amount for said natriuretic peptide indicates that said subject is not eligible to a continuation of said anti-angiogenesis therapy. For said subject a therapy other than an anti-angiogenesis therapy shall be considered.

If, in a sample of a subject, (i) the amount of a cardiac Troponin is larger than the reference amount for said cardiac Troponin and the amount of a natriuretic peptide is lower than the reference amount for a natriuretic peptide, or (ii) the amount of a cardiac Troponin is lower than the reference amount for said cardiac Troponin and the amount of a natriuretic peptide is larger than the reference amount for a natriuretic peptide, said subject needs to be carefully monitored if said anti-angiogenic therapy is continued. Particularly, the amount of the cardiac Troponin and the natriuretic peptide shall be determined on a regular basis.

The definitions and explanations of the terms made above and below apply mutatis mutandis for all embodiments/methods described in this specification and the accompanying claims (except if the contrary is indicated).

Moreover, the present invention also relates to a method for predicting the risk of an acute cardiovascular event said acute cardiovascular event, preferably, being a consequence of anti-angiogenesis therapy, comprising the steps of

a) determining the amount of a cardiac Troponin in a sample of said subject who is on anti-angiogenesis therapy,

b) comparing the amount of a cardiac Troponin as determined in step a) with suitable reference amount for a cardiac Troponin, and

c) predicting the risk of an acute cardiovascular event for a subject who is on anti-angiogenesis therapy.
Preferably, the aforementioned method further comprises determining the amount of a natriuretic peptide in a sample of the subject and comparing the, thus, determined amount to a reference amount.

The term "predicting" as used to assessing the probability according to which said subject will develop a cardiovascular event, preferably an acute cardiovascular event within a defined time window (predictive window) in the future. Preferably, said acute cardiovascular event is a consequence, i.e. an adverse side effect of said therapy.

The predictive window is an interval in which the subject will develop a cardiovascular event according to the predicted probability. The predictive window may be the entire remaining lifespan of the subject upon analysis by the method of the present invention. Preferably, however, the predictive window is an interval of one month, six months or one, two, three, four, five or ten years after carrying out the method of the present invention (more preferably and precisely, after the sample to be analyzed by the method of the present invention has been obtained). As will be understood by those skilled in the art, such an assessment is usually not intended to be correct for 100% of the subjects to be analyzed (e.g. since it is known that a cardiovascular event also can have causes other than anti-angiogenesis therapy). The term, however, requires that the assessment will be valid for a statistically significant portion of the subjects to be analyzed. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test, etc.. Details are found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99 %. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. Preferably, the probability envisaged by the present invention allows that the prediction will be correct for at least 60%, at least 70%, at least 80%, or at least 90% of the subjects of a given cohort.

The term "predicting the risk of an acute cardiovascular event" as used herein means that the subject to be analyzed by the method of the present invention is allocated either into the group of subjects of a population having a normal, i.e. non-elevated and, thus, average risk for developing an acute cardiovascular event, or into a group of subjects having a elevated risk, or into a group of subjects having a significantly elevated risk. An elevated risk as referred to in accordance with the present invention also means that the risk of developing a cardiovascular event within a predetermined predictive window is elevated for a subject
with respect to the average risk for a cardiovascular event in a population of subjects as defined herein. Preferably, for a predictive window of one year, the average risk is within the range 1.5 and 2.0 %, preferably, lower than 2.0 %. An elevated risk as used herein, preferably, relates to a risk of more than 2.0 %, preferably, more than 4.0 %, and, most preferably within 3.0 % and 5.0 %, with respect to a predictive window of one year. A significantly elevated risk as used herein, preferably relates to a risk more than 5.0 %, preferably within the range of 5.0 % and 8.0 %, or even higher with respect to a predictive window of one year.

Acute cardiovascular events are, preferably, acute coronary syndromes (ACS). ACS patients can show unstable angina pectoris (UAP) or myocardial infarction (MI). MI can be an ST-elevation MI (STEMI) or a non-ST-elevated MI (NSTEMI). The occurring of an ACS can be followed by a left ventricular dysfunction (LVD) and symptoms of heart failure. How to diagnose an acute cardiovascular event is well known in the art.

Preferably, an amount of a cardiac Troponin in a sample of a subject larger than the reference amount is indicative for a subject being at elevated risk of an acute cardiovascular event (for preferred reference amounts see herein above).

Preferably, an amount of a cardiac Troponin in a sample of a subject lower than the reference amount is indicative for a subject not being at elevated risk, and, thus, being on average risk for an acute cardiovascular event (for preferred reference amounts see herein above).

If also a natriuretic peptide is determined, the following applies:

Preferably, an amount of a cardiac Troponin lower than the reference amount for said cardiac Troponin, and an amount of a natriuretic peptide lower than the reference amount for said natriuretic peptide is indicative for a subject not being at elevated risk, and, thus, being on average risk for an acute cardiovascular event (for preferred reference amounts see herein above).

Preferably, an amount of a cardiac Troponin larger than the reference amount for said cardiac Troponin, and an amount of a natriuretic peptide larger than the reference amount for said natriuretic peptide is indicative for a subject being at elevated risk of an acute cardiovascular event. (for preferred reference amounts see herein above).
By carrying out the steps of the aforementioned method, also the risk of suffering from other side effects of anti-angiogenesis therapy, particularly, the risk of suffering from hypertension, heart failure, or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina), preferably, as a consequence of the said therapy can be predicted for a subject as defined above.

Moreover, the present invention also relates to a method for predicting the risk of an acute cardiovascular event, said acute cardiovascular event, preferably, being a consequence of anti-angiogenesis therapy in a subject being on anti-angiogenesis therapy, comprising the steps of

a) determining the amount of a cardiac Troponin in a first sample of said subject,
b) determining the amount of a cardiac Troponin in a second sample of said subject,
c) comparing the amount of the cardiac Troponin as determined in step a) with the amount of the cardiac Troponin as determined in step b), wherein an increase of the amount as determined in step b) compared with the amount as determined in step a) indicates that said subject is at elevated risk of suffering from an acute cardiovascular event, preferably, as a consequence of said therapy.

Moreover, the aforementioned method of the present invention, preferably, further comprises the step of determining the amount of natriuretic peptide in said first sample and in said second sample of said subject (and optionally in at least one further sample) and comparing the amount of said natriuretic peptide as determined for said first sample with the amount of said natriuretic peptide in said second sample. Preferably, an increase of a natriuretic peptide in the time course of an anti-angiogenesis therapy, more preferably a significant increased, and most preferably, a statistically significant increase indicates that said subject is at elevated risk of suffering from an acute cardiovascular event as a consequence of said therapy (if also the cardiac troponin is increased). Accordingly, a decreased amount (or unchanged amount, and preferably also insignificantly increased amounts, indicates that said subject is not at elevated risk of suffering from an acute cardiovascular event as a consequence of the anti-angiogenesis therapy.

Preferred increases for a cardiac Troponin and a natriuretic peptide are indicated elsewhere in this specification.
By carrying out the steps of the aforementioned method, also the risk of suffering from hypertension, heart failure, or other vascular events (particularly, stroke, peripheral arterial disease, and/or abdominal angina), preferably, as a consequence of the said therapy can be predicted for a subject as defined above.

Moreover, the present invention relates to a device for monitoring a subject being on anti-angiogenesis therapy, comprising means for determining the amount of a cardiac Troponin (preferably Troponin T) in a first sample and in a second sample of said subject, and means for comparing the amount in said first sample with the amount in said second sample determined by said means, whereby it is assessed whether said subject is eligible to a continuation of said anti-angiogenesis therapy (or not).

Moreover, the present invention relates to a device for predicting the risk of an acute cardiovascular event in a subject being on anti-angiogenesis therapy, said acute cardiovascular event, preferably, being a consequence of anti-angiogenesis therapy, comprising means for determining the amount of a cardiac Troponin (preferably Troponin T) in a first sample and in a second sample of said subject, and means for comparing the amount in said first sample with the amount in said second sample determined by said means, whereby the risk of suffering from an acute cardiovascular event for said subject is predicted.

The aforementioned two devices, preferably, further comprise means for determining the amount of a natriuretic peptide in said first and said second sample of said subject and means for comparing the amount of said natriuretic peptide in said first sample with the amount of said natriuretic peptide in said second sample.

Moreover, the present invention relates to a device for identifying a subject who is eligible to a continuation of an anti-angiogenesis therapy, said subject being on anti-angiogenesis therapy, comprising means for determining the amount of a cardiac Troponin (preferably Troponin T) in a sample of said subject, and means for comparing the amount in said sample determined by said means with a reference amount, whereby it is assessed whether said subject is eligible to a continuation of said anti-angiogenesis therapy (or not).

Preferably, said device further comprises means for determining the amount of a natriuretic peptide, in particular of NT-proBNP, in said sample of said subject and means for comparing the amount determined by said means to a reference amount for a natriuretic peptide.
Moreover, the present invention relates to a device for predicting the risk of an acute cardiovascular event in a subject being on anti-angiogenesis therapy, said acute cardiovascular event, preferably, being a consequence of anti-angiogenesis therapy, comprising means for determining the amount of a cardiac Troponin (preferably Troponin T) in a sample of said subject, and means for comparing the amount in said sample determined by said means with a reference amount, whereby the risk of suffering from an acute cardiovascular event for said subject is predicted.

Preferably, said device further comprises means for determining the amount of a natriuretic peptide, in particular of NT-proBNP, in said sample of said subject and means for comparing the amount determined by said means to a reference amount for a natriuretic peptide.

The term "device" as used herein relates to a system of means comprising at least the aforementioned means operatively linked to each other as to allow the identification of subjects being eligible to a continuation of anti-angiogenesis therapy or for predicting the risk of an acute cardiovascular event for a subject being on anti-angiogenesis therapy. Preferred means for determining the amount of a cardiac Troponin and a natriuretic peptide, and means for carrying out the comparison are disclosed above in connection with the method of the invention. How to link the means in an operating manner will depend on the type of means included into the device. For example, where means for automatically determining the amount of the peptides are applied, the data obtained by said automatically operating means can be processed by, e.g., a computer program in order to obtain the desired results. Preferably, the means are comprised by a single device in such a case. Said device may accordingly include an analyzing unit for the measurement of the amount of the peptides or polypeptides in an applied sample and a computer unit for processing the resulting data for the evaluation. Alternatively, where means such as test stripes are used for determining the amount of the peptides or polypeptides, the means for comparison may comprise control stripes or tables allocating the determined amount to a reference amount.

The test stripes are, preferably, coupled to a ligand which specifically binds to the peptides or polypeptides referred to herein. The strip or device, preferably, comprises means for detection of the binding of said peptides or polypeptides to the said ligand. Preferred means for detection are disclosed in connection with embodiments relating to the method of the invention above. In such a case, the means are operatively linked in that the user of the system brings together the result of the determination of the amount and the diagnostic or prognostic value thereof due to the instructions and interpretations given in a manual. The means may appear as separate devices in such an embodiment and are, preferably, packaged together as a kit. The person skilled in the art will realize how to link the means
without further ado. Preferred devices are those which can be applied without the particular knowledge of a specialized clinician, e.g., test stripes or electronic devices which merely require loading with a sample. The results may be given as output of raw data which need interpretation by the clinician. Preferably, the output of the device is, however, processed, i.e. evaluated, raw data the interpretation of which does not require a clinician. Further preferred devices comprise the analyzing units/devices (e.g., biosensors, arrays, solid supports coupled to ligands specifically recognizing the polypeptide whose amount shall be determined, Plasmon surface resonace devices, NMR spectrometers, mass-spectrometers etc.) or evaluation units/devices referred to above in accordance with the method of the invention.

Moreover, the present invention relates to a kit for monitoring a subject being on anti-angiogenesis therapy, said kit comprising instructions for carrying out the said method, and means for determining the amount of a cardiac Troponin (preferably Troponin T) in a first sample and in a second sample of said subject, and means for comparing the amount in said first sample with the amount in said second sample determined by said means, allowing assessing whether said subject is eligible to a continuation of said anti-angiogenesis therapy (or not).

Moreover, the present invention relates to a kit for predicting the risk of an acute cardiovascular event in a subject being on anti-angiogenesis therapy, said acute cardiovascular event, preferably, being a consequence of anti-angiogenesis therapy, said kit comprising instructions for carrying out the said method, and means for determining the amount of a cardiac Troponin (preferably Troponin T) in a first sample and in a second sample of said subject, and means for comparing the amount in said first sample with the amount in said second sample determined by said means, allowing prediction the risk of suffering from an acute cardiovascular event as a consequence of said therapy for said subject.

The aforementioned two kits, preferably, further comprise means for determining the amount of a natriuretic peptide in said first and said second sample of said subject and means for comparing the amount of said natriuretic peptide in said first sample with the amount of said natriuretic peptide in said second sample.

Also envisaged by the present invention is a kit adapted to carry out the method of the present invention, said kit comprising instructions for carrying out the said method, and means for determining the amounts of a cardiac Troponin (preferably Troponin T) in a sample of a subject in need of an anti-angiogenesis therapy, and means for comparing the
amount determined by said means to a reference amount for a cardiac troponin (preferably Troponin T) allowing identifying a subject being eligible to a continuation of said a anti-angiogenesis therapy and/or predicting the risk of an acute cardiovascular event in a subject who is on anti-angiogenesis therapy.

Preferably, said kit further comprises means for determining the amount of a natriuretic peptide, in particular of NT-proBNP, in said sample of said subject and means for comparing the amount determined by said means to a reference amount for a natriuretic peptide.

Also envisaged by the present invention is a kit adapted to carry out the method of the present invention, said kit comprising instructions for carrying out the said method, and means for determining the amounts of a cardiac Troponin (preferably Troponin T) in a sample of a subject in need of an anti-angiogenesis therapy, and means for comparing the amount determined by said means to a reference amount for a cardiac troponin (preferably Troponin T) allowing predicting the risk of an acute cardiovascular event in a subject who is on anti-angiogenesis therapy, said acute cardiovascular event, preferably, being a consequence of said anti-angiogenesis therapy.

Preferably, said kit further comprises means for determining the amount of a natriuretic peptide, in particular of NT-proBNP, in said sample of said subject and means for comparing the amount determined by said means to a reference amount for a natriuretic peptide.

The term "kit" as used herein refers to a collection of the aforementioned compounds, means or reagents of the present invention which may or may not be packaged together. The components of the kit may be comprised by separate vials (i.e. as a kit of separate parts) or provided in a single vial. Moreover, it is to be understood that the kit of the present invention is to be used for practising the methods referred to herein above. It is, preferably, envisaged that all components are provided in a ready-to-use manner for practising the methods referred to above. Further, the kit preferably contains instructions for carrying out the said methods. The instructions can be provided by a users manual in paper- or electronic form. For example, the manual may comprise instructions for interpreting the results obtained when carrying out the aforementioned methods using the kit of the present invention.
Finally, the present invention relates to the use of a cardiac Troponin and, optionally, a natriuretic peptide, in a sample of a subject, for identifying a subject being eligible to a continuation of an anti-angiogenesis therapy and/or for predicting the risk of suffering from an acute cardiovascular event as a consequence of anti-angiogenesis therapy.

All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.

The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.

**Example 1: Determination of Troponin T and NT-proBNP in serum and plasma samples**

Troponin T and NT-proBNP were determined in a collective of 324 patients suffering from various forms of tumors. Surprisingly, a majority of tumor patients (56%) had NT-proBNP level larger than 125 pg/ml indicating heart failure. Moreover, 85% of tumor patients had detectable levels of Troponin T (levels larger than 1 pg/ml of Troponin T indicating necrosis of cardiac tissue. In 29% of the patients even Troponin T levels of larger than 10 pg/ml were measured.

**Example 2:**

A 65 years old patient with type 2 Diabetes mellitus (duration 15 years) is diagnosed of suffering from advanced colorectal cancer. Before initiating a therapy with an anti-VEGF antibody, the amounts of Troponin T (4 pg/ml) and NT-proBNP (240 pg/ml) are determined in a serum sample obtained from said patient. Echocardiography and ECG indicate the subject does not suffer from a significant cardiac dysfunction. After said patient has taken the anti-VEGF antibody for two weeks, a new serum sample is obtained from said patient, and the amounts of Troponin T and NT-proBNP are determined again. In the new sample the amounts of said Troponin T (4.2 pg/ml) and NT-pro-BNP (250 pg/ml) do not show a significant change compared with the amounts in the sample obtained prior to administering anti-VEGF. However, in a sample three month after initiation of the anti-angiogenesis therapy, the amount of Troponin T is 7.5 pg/ml (NT-proBNP 270 pg/ml), after four months even 12 pg/ml (NT-proBNP 350 pg/ml). Five months after the start of anti-angiogenesis therapy, the subject suffers from a myocardial infarction.
Example 2:

A 62 years old male patient and previous smoker suffers from a myocardial infarction. Three years later, advanced colorectal cancer is diagnosed necessitating a suitable cancer therapy. The left ventricular ejection fraction (LVEF) is determined by echocardiography (40 %) indicating a minor systolic dysfunction. Moreover, the amounts of a Troponin T (12 pg/ml) and NT-proBNP (510 pg/ml) are determined in a sample of the patient. The patient is subjected to a cardiac stress test showing that a region of the posterior myocardial wall has a dysfunctional contractility (reversible perfusion defects). Coronary angiography is carried out indicating 80 % stenosis of the artery that supplies the region of dysfunctional contractility with blood. Two weeks after successful revascularization of the affected myocardial regions, Troponin T (6 pg/ml) and NT-proBNP (180 pg/ml) are determined again. A therapy with VEGF-inhibitors is started; Troponin T and NT-proBNP are measured monthly. During the therapy with VEGF-inhibitors the levels of these two biomarkers remain stable. Also, the therapy is effective indicated by a reduced tumor size as well as by reduced CEA levels (carcinoembryonic antigen). During the therapy, the patient does not suffer from adverse side effects of the therapy.

Example 3:

Levels of Troponin T and/or NT-proBNP were determined in serum samples obtained from 27 patients treated with Bevacizumab before the therapy was started and during therapy. In the majority of patients (more than 80%), the levels of the markers remained unchanged, i.e. there was no significant increase indicating that the therapy did not have adverse side effects on the cardiovascular system. In some patients, however, there was a significant increase of the measured markers indicating a risk of cardiovascular complications. Examples are shown herein below.

Patient (ID No: 4201): Samples were obtained at the start of the therapy, as well as 14, 21 and 35 days after the therapy was started (no adverse side effects on the cardiovascular system)

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sample obtained (d)</th>
<th>Troponin T (pg/ml)</th>
<th>NT-proBNP (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4201</td>
<td>0</td>
<td>4</td>
<td>38</td>
</tr>
</tbody>
</table>
Patient (ID No: 4208): Troponin T and NT-proBNP 13 and 57 days after the therapy was started. Significant increases of the measured markers were observed indicating a risk of cardiovascular complications.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sample obtained (d)</th>
<th>Troponin T (pg/ml)</th>
<th>NT-proBNP (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4208</td>
<td>13</td>
<td>13</td>
<td>296</td>
</tr>
<tr>
<td>4208</td>
<td>57</td>
<td>44</td>
<td>844</td>
</tr>
</tbody>
</table>

Patient (ID No: 4210): Samples were obtained at the start of the therapy as well as 14 days after the therapy was started. At treatment initiation, the Troponin T level was significantly increased (also the NT-proBNP level: 1916 pg/ml). During treatment, there was a further increase of Troponin T indicating an enhanced risk of cardiovascular complication.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sample obtained (d)</th>
<th>Troponin T (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4210</td>
<td>0</td>
<td>42</td>
</tr>
<tr>
<td>4210</td>
<td>14</td>
<td>80</td>
</tr>
</tbody>
</table>
Claims

1. A method for monitoring anti-angiogenesis therapy for a subject, comprising the steps of
   a) determining the amount of a cardiac Troponin in a first sample of said subject,
   b) determining the amount of a cardiac Troponin in a second sample of said subject,
   c) comparing the amount of the cardiac Troponin as determined in step a) with the amount of the cardiac Troponin as determined in step b), wherein an increase of the amount as determined in step b) compared with the amount as determined in step a) indicates that said subject is not eligible to a continuation of the said anti-angiogenesis therapy.

2. The method of claim 1, wherein said first sample is obtained prior to the start or at the start of the anti-angiogenesis therapy, and wherein said second sample is obtained after the start of the anti-angiogenesis therapy.

3. The method of claims 1 and 2, wherein the second sample is obtained at least two months after the first sample was obtained.

4. The method of any one of claims 1 to 3, wherein said subject suffers from cancer.

5. The method of any one of claims 1 to 4, wherein the anti-angiogenesis therapy is by administration of an anti-VEGF antibody.

6. The method of any one of claims 1 to 5, wherein said cardiac Troponin is Troponin T and/or wherein an increase of 3 pg/ml of the amount of said cardiac Troponin indicates that said subject is not eligible to a continuation of the said anti-angiogenesis therapy.

7. The method of any one of claims 1 to 6, further comprising determining the amount of a natriuretic peptide in said sample first sample and in said second sample of said subject and comparing the amount of said natriuretic as determined for said first sample with the amount as determined for said second sample.
8. The method of claim 7, wherein an increase of the amount of said natriuretic peptide compared in said second sample compared with the amount of said natriuretic peptide in said second sample further indicates that said subject is not eligible to a continuation of the said anti-angiogenesis therapy.

9. The method of any one of claims 1 to 8, comprising determining the amount of cardiac Troponin and, optionally, the amount of a natriuretic peptide in at least one further sample and comparing the amount of said cardiac Troponin and, optionally, the amount of said natriuretic peptide to the amount in said first sample and/or said second sample, and/or in any sample that was obtained prior to said at least one further sample.

10. A method for identifying a subject being eligible to a continuation of an anti-angiogenesis therapy, said subject being on anti-angiogenesis therapy, comprising the steps
   a) determining the amount of a cardiac Troponin in a sample of said subject,
   b) comparing the amount of said cardiac Troponin as determined in step a) with a reference amount for said cardiac Troponin, and
   c) identifying a subject being eligible to a continuation of anti-angiogenesis therapy.

11. A method for predicting the risk of an acute cardiovascular event for a subject who is on anti-angiogenesis therapy, said acute cardiovascular event, preferably, being a consequence of said therapy comprising the steps of
   a) determining the amount of a cardiac Troponin in a sample of said subject
   b) comparing the amount of a cardiac Troponin as determined in step a) with a reference amount for a cardiac Troponin, and
   c) predicting the risk of an acute cardiovascular event for said subject.

12. The method of claim 10 or 11, further comprising determining the amount of a natriuretic peptide and comparing the, thus, determined amount to a reference amount for a natriuretic peptide.

13. A device for monitoring anti-angiogenesis therapy for a subject comprising means for determining the amount of a cardiac Troponin in a first sample and in a second sample of a subject being on anti-angiogenesis therapy, and means for comparing the amount in said first sample with the amount in said second sample determined by
said means, allowing assessing whether a subject is eligible to a continuation of the said therapy.

14. A kit adapted to carry out the method of any one of claims 1 to 9, said kit comprising instructions for carrying out the said method, and means for determining the amount of a cardiac Troponin in a first sample and in a second sample of a subject being on anti-angiogenesis therapy, and means for comparing the amount in said first sample with the amount in said second sample determined by said means, allowing assessing whether a subject is eligible to a continuation of the said therapy.

15. The device of claim 13, or the kit of claim 14, further comprising means for determining the amount of a natriuretic peptide in the first sample and in the second sample of said subject and means for comparing the amount of said natriuretic peptide in said first sample with the amount of said natriuretic peptide in said second sample.
A. CLASSIFICATION OF SUBJECT MATTER

INV. G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

GOIN

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Citation of document with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X Powerpoint presentation from the oral presentation at the official ECCO14 satellite symposium ECCO 14, 23-27 September 2007 XP002501781 Biomarker research: evolution or revolution? Changing clinical practice in lung cancer retrieved via <a href="http://www.egfr.roche.es/ECC0/">www.egfr.roche.es/ECC0/</a> the whole document</td>
<td>1-12</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C

X See patent family annex

Special categories of cited documents

'A' document defining the general state of the art which is not considered to be of particular relevance

'Early' earlier document but published on or after the international filing date

'Later' document which may throw doubts on a specific claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

'O' document referring to an oral disclosure, use, exhibition or other means

'P' document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

23 October 2009

Date of mailing of the international search report

05/11/2009

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentaal 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040 Fax (+31-70) 340-3016

Authorized officer

Wiesner, Martin
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>JONES ET AL: &quot;Early Breast Cancer Therapy and Cardiovascular Injury&quot;</td>
<td>1-12</td>
</tr>
<tr>
<td></td>
<td>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>vol. 50, no. 15, 2 October 2007 (2007-10-02), pages 1435-1441, XP022310021</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISSN: 0735-1097 page 1438, left-hand column, paragraph 5; table 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 1439, left-hand column, paragraph 2</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>ADAMCOVA ET AL: &quot;Troponin as a marker of myocardial damage in drug-induced cardiototoxicity&quot;</td>
<td>1-12</td>
</tr>
<tr>
<td></td>
<td>EXPERT OPINION DRUG SAFETY, vol. 4, no. 3, 2005, pages 457-472, XP008098071</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 458, right-hand column, paragraph 2; table 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 467, right-hand column, paragraph 1</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>DOLCI A ET AL: &quot;Biochemical markers for prediction of chemotherapy-induced cardiototoxicity: Systematic review of the literature and recommendations for use&quot;</td>
<td>1-12</td>
</tr>
<tr>
<td></td>
<td>AMERICAN JOURNAL OF CLINICAL PATHOLOGY, AMERICAN SOCIETY FOR CLINICAL PATHOLOGY, US,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>vol. 130, no. 5, 1 January 2008 (2008-01-01), pages 688-695, XP009110605</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISSN: 0002-9173 page 690, right-hand column, paragraph 4; page 692, right-hand column, paragraph 5; table 1</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>DOLCI A ET AL: &quot;Biochemical markers for predicting chemotherapy-induced cardiototoxicity: Systematic review of the literature and recommendations for use&quot;</td>
<td>1-12</td>
</tr>
<tr>
<td></td>
<td>GIORNALE ITALIANO DI CARDIOLOGIA, vol. 7, no. 9, 1 January 2006 (2006-01-01), pages 604-611, XP001538665</td>
<td></td>
</tr>
<tr>
<td></td>
<td>abstract table 1</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>X</td>
<td>LANGER B ET AL. &quot;Prospective investigation of the significance of cardiac markers, NT-pro Brain Natriuretic Peptide (NT-proBNP) and Troponin T (TnT), in the HERCULES study of epirubicin/cyclophosphamide with or without trastuzumab (Herceptin(R))&quot; EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, Pergamon, Oxford, GB, vol. 2, no. 3, 16 March 2004 (2004-03-16), page 143, XP002510616 ISSN: 1359-6349 abstract</td>
<td>1-12</td>
</tr>
<tr>
<td>X</td>
<td>EP 1 837 659 A (HOFFMANN LA ROCHE [CH]; ROCHE DIAGNOSTICS GMBH [DE]) 26 September 2007 (2007-09-26) page 7, paragraph 37; claims 13,14; tables 1,2</td>
<td>13-15</td>
</tr>
<tr>
<td>A</td>
<td>WO 02/089657 A (BIOSITE INC [US]; VALKIRS GUNARS E [US]; DAHLEN JEFFREY R [US]; KIRCHI) 14 November 2002 (2002-11-14) example 3</td>
<td>1-15</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>A</td>
<td>SCIRICA B M ET AL: &quot;Troponins in acute coronary syndromes&quot; PROGRESS IN CARDIOVASCULAR DISEASES, SAUNDERS, PHILADELPHIA, PA, US, vol. 47, no. 3, 1 November 2004 (2004-11-01), pages 177-188, XP004694015 ISSN: 0033-0620 page 184, column 2, last line - page 185, column 1, line 11; figure 10</td>
<td>1-15</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101410716 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1999475 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2007110359 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009087918 A1</td>
</tr>
<tr>
<td>WO 02089657 A</td>
<td>14-11-2002</td>
<td>AT 439588 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2414073 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1322957 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3806694 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004520598 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005121664 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4235652 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2006234823 A</td>
</tr>
</tbody>
</table>